Navigation Links
Reportlinker Adds Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics
Date:12/8/2010

NEW YORK, Dec. 8, 2010 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics

http://www.reportlinker.com/p0336651/Personalized-Medicine-Market---Advances-in-Human-Genomics-and-Proteomics-to-Challenge-Traditional-Therapeutics.html

Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics

SummaryGBI Research, the leading business intelligence provider, has released its latest report, "Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics" that provides key data, information and analysis of the major trends and issues in Personalized Medicine Market. The report provides a comprehensive insight into the role of Human Genomics and Proteomics to challenge traditional therapeutics. The report also provides a detailed analysis of market characterization of personalized medicine market in terms of its market size, segmentation by key geography types and the major market drivers and barriers. The report also talks about the patent landscape for human genomics and proteomics and provides comprehensive analysis.

Scope

The scope of the report includes:

- Detailed overview of Personalized Medicine Market in pharmaceutical industry along with their use, efficiency and limitation.

- Annualized market data from 2007 and forecast forward till 2016 along with segmentation by geography.

- Key market drivers and restraints shaping the Personalized Medicine Market.

- Competitive landscape analysis with competitive profiling of leading companies.

- Analysis of partnership deals from 2006 to 2010

- Analysis of M&A deals from 2005 to 2010 along with segmentation by value geography and companies.

Reasons to buyThe report will enhance your decision making capability. It will allow you to

- Develop better strategies for personalized medicine market research by understanding the market dynamics.

- Develop market-entry and market expansion strategies by identifying the key development area

- Understand the factors shaping the Personalized Medicine Market

- For understanding the role of Human Genomics and Proteomics to challenge traditional therapeutics.

- Identify the key players best positioned to take the advantage of the opportunities in the global market.

- Exploit partnership and acquisition opportunities by identifying the products that could fill the portfolio gaps.

1 Table of Contents 4

1.1 List of Tables 7

1.2 List of Figures 9

2 Personalized Medicine Market: Market Overview 10

2.1 Introduction 10

2.1.1 Potential Applications of Personalized Medicine 12

2.2 GBI Research Report Guidance 14

3 Personalized Medicine Market: Drivers and Barriers 15

3.1 Drivers 16

3.1.1 Increase in healthcare costs 16

3.1.2 Advantages over conventional drug discovery methods 16

3.1.3 Patient compliance 16

3.1.4 Early detection of disease 17

3.1.5 Better regulatory norms and validation procedures encourage growth of the personalized medicine market 17

3.2 Barriers 17

3.2.1 Payer Reimbursement Issues 17

3.2.2 Ethical Issues 17

3.2.3 Medical Information Technology 18

3.2.4 Awareness Gap – Lack of Physician Education and Awareness about Novel Technologies 18

3.2.5 Cumbersome and Lengthy Development Procedure Discourages Biomarker Research by the Pharmaceutical Sector 18

4 Personalized Medicine Market – Personalized Therapeutics and Diagnostics 19

4.1 Personalized Therapeutics – Drug Profiles 19

4.1.1 Herceptin (trastuzumab) 19

4.1.2 Erbitux (cetuximab) 24

4.1.3 Gleevec (imatinib) 28

4.1.4 Zyprexa (olazapine) 32

4.1.5 Lipitor (atorvastatin) 35

4.1.6 Celebrex (celecoxib) 39

4.1.7 Tarceva (erlotinib) 42

4.1.8 Rituxan (rituximab) 46

4.1.9 Plavix (clopidogrel bisulfate) 49

4.1.10 Risperdal (risperidone) 51

4.1.11 Vectibix (Panitumumab) 54

4.1.12 Coumadin (Warfarin) 56

4.1.13 Iressa (Gefitinib) 57

4.1.14 Sprycel 59

4.1.15 Camptosar 61

4.2 Companion Diagnostics 62

4.2.1 Selected Companion Diagnostics Employed in Personalized Healthcare 64

4.3 Biomarkers 67

4.3.1 Biomarkers in Cancer Research 68

4.3.2 Market Size and Forecasts 69

4.3.3 Segmentation by Indication 70

5 Personalized Medicine Market: Selected Pipeline Product Profiles 80

5.1 PF-4948568 (Pfizer) 80

5.1.1 Overview 80

5.1.2 Mechanism of Action 80

5.1.3 Clinical Study Details 80

5.2 PF-02341066 + Erlotinib (Pfizer) 81

5.2.1 Overview 81

5.2.2 Mechanism of Action 81

5.2.3 Clinical study details 81

5.3 PF-299804 (Pfizer) 82

5.3.1 Overview 82

5.3.2 Mechanism of action 82

5.3.3 Clinical study details 82

5.4 CEP-701 (Cephalon Inc.) 83

5.4.1 Overview 83

5.4.2 Mechanism of action 83

5.4.3 Clinical study details 84

5.5 TBR-652 (Tobira Therapeutics, Inc) 84

5.5.1 Overview 84

5.5.2 Mechanism of action 84

5.5.3 Clinical study details 85

5.6 Brivanib (Bristol-Myers Squibb) 85

5.6.1 Overview 85

5.6.2 Mechanism of action 85

5.6.3 Clinical study details 86

5.7 Ipilimumab (Bristol-Myers Squibb) 86

5.7.1 Overview 86

5.7.2 Mechanism of Action 86

5.7.3 Clinical Study Details 86

5.8 BiovaxID (Accentia Biopharmaceuticals, Inc.) 87

5.8.1 Overview 87

5.8.2 Mechanism of Action 87

5.8.3 Clinical Study Details 87

6 Personalized Medicine Market: Research Trends in Personalized Medicine 88

7 Personalized Medicine Market: Competitive Landscape 89

7.1 Competitive Profiling 89

7.2 Clarient, Inc. 89

7.2.1 Business Description 89

7.2.2 Pipeline 90

7.2.3 Major Products 90

7.2.4 Partnership and Merger and Acquisition (M&A) Deals 91

7.3 Qiagen N.V. 92

7.3.1 Business Description 92

7.3.2 Pipeline 92

7.3.3 Major Products 92

7.3.4 Partnership and M&A Deals 94

7.4 Laboratory Corporation of America Holdings 96

7.4.1 Business Description 96

7.4.2 Pipeline 96

7.4.3 Major Products 96

7.4.4 Partnership and M&A Deals 97

7.5 bioMerieux S.A. 99

7.5.1 Business Description 99

7.5.2 Pipeline 99

7.5.3 Major Products 99

7.5.4 Partnership and M&A Deals 100

7.5.5 Partnership and M&A Deals 102

7.6 Pfizer 102

7.6.1 Business Overview 102

7.6.2 Partnership and M&A Deals 103

7.7 Eli Lily and Company 104

7.7.1 Business Overview 104

7.7.2 Partnership and M&A deals 105

7.8 Novartis 106

7.8.1 Business Overview 106

7.8.2 Partnership and M&A Deals 107

7.9 F. Hoffman La Roche 108

7.9.1 Business Overview 108

7.9.2 Diagnostics 108

7.9.3 Pharmaceuticals 109

7.9.4 Partnership and M&A Deals 110

7.10 Bristol-Myers Squibb 111

7.10.1 Business Overview 111

7.10.2 Partnership and M&A deals 112

7.11 Merck KGaA 113

7.11.1 Business Overview 113

7.11.2 Partnership and M&A deals 114

7.12 Dako Denmark A/S 116

7.12.1 Business Overview 116

7.12.2 Partnership and M&A deals 116

8 Personalized Medicine Market: Conclusion 117

9 Personalized Medicine Market: Appendix 118

9.1 Market Definitions 118

9.2 Abbreviations 118

9.3 Research Methodology 121

9.3.1 Coverage 122

9.3.2 Secondary Research 122

9.3.3 Primary Research 122

9.3.4 Expert Panel Validation 123

9.4 Contact Us 123

9.5 Disclaimer 123

9.6 Sources 1231.1 List of Tables

Table 1: Herceptin – Snapshot 2010 19

Table 2: Herceptin, Global, Revenues ($m) 2007-2009 23

Table 3: Erbitux – Snapshot 2010 24

Table 4: Erbitux, Global, Revenues ($m) 2007-2009 27

Table 5: Gleevec – Snapshot 2010 28

Table 6: Gleevec, Global, Revenues ($m) 2007-2009 31

Table 7: Zyprexa – Snapshot 2010 32

Table 8: Zyprexa, Global, Revenues ($m) 2007-2009 34

Table 9: Lipitor – Snapshot 2010 35

Table 10: Lipitor, Global, Revenues ($m) 2007-2009 38

Table 11: Celebrex – Snapshot 2010 39

Table 12: Celebrex, Global, Revenues ($m) 2007-2009 41

Table 13: Tarceva – Snapshot 2010 42

Table 14: Tarceva, Global, Revenues ($m) 2007-2009 44

Table 15: Rituxan – Snapshot 2010 46

Table 16: Rituxan, Global, Revenues ($m) 2007-2009 47

Table 17: Rituxan, Global, Revenues 2007-2009 48

Table 18: Plavix – Snapshot 2010 49

Table 19: Plavix, Global, Revenues ($m) 2007-2009 50

Table 20: Risperdal – Snapshot 2010 51

Table 21: Risperdal, Global, Revenues ($m) 2007-2009 53

Table 22: Vectibix – Snapshot 2010 54

Table 23: Coumadin – Snapshot 2010 56

Table 24: Iressa – Snapshot 2010 57

Table 25: Sprycel – Snapshot 2010 59

Table 26: Camptosar – Snapshot 2010 61

Table 27: Personalized Medicine Market, List of Selected Personalized Diagnostics and Therapeutics, 2010* 63

Table 28: Personalized Medicine Market, Biomarkers in Cancer Research, Global, Cancer Biomarkers Market Revenues ($bn), 2007–2016 69

Table 29: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Breast Cancer Biomarkers Market Revenues ($m), 2007–2016 71

Table 30: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Prostate Cancer Biomarkers Market Revenues ($m), 2007–2016 72

Table 31: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Lung Cancer Biomarkers Market Revenues ($m), 2007–2016 73

Table 32: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Colorectal Cancer Biomarkers Market Revenues ($m), 2007–2016 74

Table 33: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Cervical Cancer Biomarkers Market Revenues ($m), 2007–2016 75

Table 34: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Head and Neck Cancer Biomarkers Market Revenues ($m), 2007–2016 76

Table 35: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Pancreatic Cancer Biomarkers Market Revenues ($m), 2007–2016 77

Table 36: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Ovarian Cancer Biomarkers Market Revenues ($m), 2007–2016 78

Table 37: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Stomach Cancer Biomarkers Market Revenues ($m), 2007–2016 79

Table 38: Personalized Medicine Market, Clarient, Pipeline, August 2010 90

Table 39: Personalized Medicine Market, Clarient, Major M&A Deals, 2005–2010 91

Table 40: Personalized Medicine Market, Clarient, Partnership Deals, 2006–2010 91

Table 41: Personalized Medicine Market, QIAGEN, Pipeline, August 2010 92

Table 42: Personalized Medicine Market, QIAGEN, Major M&A Deals, 2005–2010 94

Table 43: Personalized Medicine Market, QIAGEN, Partnership Deals, 2006–2010 95

Table 44: Personalized Medicine Market, Laboratory Corporation of America Holdings, Pipeline, August 2010 96

Table 45: Personalized Medicine Market, Laboratory Corporation of America Holdings, Major M&A Deals, 2005–2010 97

Table 46: Personalized Medicine Market, Laboratory Corporation of America Holdings, Partnership Deals, 2006–2010 98

Table 47: Personalized Medicine Market, bioMerieux, Pipeline, August 2010 99

Table 48: Personalized Medicine Market, bioMerieux, Major M&A Deals, 2005–2010 100

Table 49: Personalized Medicine Market, bioMerieux, Partnership Deals, 2006–2010 101

Table 47: Personalized Medicine Market, Biomoda, Partnership Deals, 2006–2010 1021.2

List of FiguresFigure 1: Personalized Medicine Market, Potential Applications of Personalized Medicine 12

Figure 2: Personalized Medicine Market, Market Drivers and Restraints, 2010 15

Figure 3: Herceptin, Global, Revenues ($m) 2007-2009 23

Figure 4: Herceptin – SWOT 2010 24

Figure 5: Erbitux, Global, Revenues ($m) 2007-2009 27

Figure 6: Erbitux – SWOT 2010 28

Figure 7: Gleevec, Global, Revenues ($m) 2007-2009 31

Figure 8: Gleevec – SWOT 2010 32

Figure 9: Zyprexa, Global, Revenues ($m) 2007-2009 34

Figure 10: Zyprexa – SWOT 2010 35

Figure 11: Lipitor, Global, Revenues ($m) 2007-2009 38

Figure 12: Lipitor – SWOT 2010 39

Figure 13: Celebrex, Global, Revenues ($m) 2007-2009 41

Figure 14: Celebrex – SWOT 2010 42

Figure 15: Tarceva, Global, Revenues ($m) 2007-2009 44

Figure 16: Tarceva – SWOT 2010 45

Figure 17: Rituxan, Global, Revenues ($m) 2007-2009 47

Figure 18: Rituxan – SWOT 2010 48

Figure 19: Plavix, Global, Revenues ($m) 2007-2009 50

Figure 20: Plavix– SWOT 2010 51

Figure 21: Risperdal, Global, Revenues ($m) 2007-2009 53

Figure 22: Risperdal – SWOT 2010 54

Figure 23: Personalized Medicine Market, Biomarkers in Cancer Research, 2010 68

Figure 24: Personalized Medicine Market, Biomarkers in Cancer Research, Global, Cancer Biomarkers Market Revenues ($bn), 2007–2016 69

Figure 25: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Market Segmentation by Indication, 2009 70

Figure 26: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Breast Cancer Biomarkers Market Revenues ($m), 2007–2016 71

Figure 27: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Prostate Cancer Biomarkers Market Revenues ($m), 2007–2016 72

Figure 28: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Lung Cancer Biomarkers Market Revenues ($m), 2007–2016 73

Figure 29: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Colorectal Cancer Biomarkers Market Revenues ($m), 2007–2016 74

Figure 30: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Cervical Cancer Biomarkers Market Revenues ($m), 2007–2016 75

Figure 31: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Head and Neck Cancer Biomarkers Market Revenues ($m), 2007–2016 76

Figure 32: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Pancreatic Cancer Biomarkers Market Revenues ($m), 2007–2016 77

Figure 33: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Ovarian Cancer Biomarkers Market Revenues ($m), 2007–2016 78

Figure 34: Personalized Medicine Market, Global, Biomarkers in Cancer Research, Stomach Cancer Biomarkers Market Revenues ($m), 2007–2016 79

Figure 35: Research and Innovation Trends in Personalized Medicine 88

Figure 36: Personalized Medicine Market, Global, Geographic Landscape, 2009 89

Companies mentioned To order this report:Genomics Industry: Personalized Medicine Market - Advances in Human Genomics and Proteomics to Challenge Traditional Therapeutics

Genomics Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!CONTACT:Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Reportlinker Adds Global Flow Cytometers Industry
2. Reportlinker Adds World Biometrics Market
3. Reportlinker Adds Global Biometrics Industry
4. Reportlinker Adds Biomarkers - technologies, markets and companies
5. Reportlinker Adds Proteomics: Technologies and Global Markets Report
6. Reportlinker Adds World Dynamic Signature Verification Market Report
7. Reportlinker Adds Carbon Dioxide Monitors Report
8. Personalized diets for elderly after hospitalization decreases mortality rates
9. OGI invests in personalized medicine for age-related macular degeneration
10. AACR congratulates William S. Dalton on 2010 Leadership in Personalized Medicine Award
11. With growing US support for personalized medicine, a look at ethical dilemmas
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/2/2016)... , Feb. 2, 2016 Technology Enhancements Accelerate ... an analysis of the digital and computed radiography markets ... , and Indonesia (TIM). ... and market size, as well as regional market drivers ... and discusses market penetration and market attractiveness, both for ...
(Date:2/1/2016)...  Wocket® smart wallet ( www.wocketwallet.com ) announces the launch of a ... . Las Vegas , where Joey appeared at ... Las Vegas , where Joey appeared at the Wocket booth ... ad was filmed at the Consumer Electronics Show (CES2016) in ... meet and greet fans. --> --> ...
(Date:1/22/2016)... 22, 2016 ... of the  "Global Behavioral Biometric Market ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ... Biometric Market 2016-2020"  report to their ... Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ...
Breaking Biology News(10 mins):
(Date:2/10/2016)... Miami, FL (PRWEB) , ... February 10, 2016 ... ... leader in regenerative medicine, has announced a new agreement with Singapore-based Global Stem ... qualified physicians from the Philippines, Thailand and Singapore in the latest adipose and ...
(Date:2/9/2016)... LITTLE FALLS, N.J. , Feb. 9, 2016 ... ), a biotechnology company specializing in the development ... the health of damaged tissues and organs, recently ... milestones for the first quarter of 2016. ... Regenicin began the new 2015 fiscal year in ...
(Date:2/9/2016)... Prussia, PA (PRWEB) , ... February 09, 2016 , ... ... Development, Europe. Based in Paris, he will focus on acquiring new accounts and ... being met. , “Fred brings to our European clients more than ...
(Date:2/9/2016)... 9, 2016  DNAtrix, a clinical stage, ... announced that its lead product, DNX-2401, has ... an orphan medicinal product for the treatment ... glioma, strikes approximately 25,000 people a year ... http://photos.prnewswire.com/prnh/20160208/330986LOGO --> http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
Breaking Biology Technology: